## Supplementary Information

## Bivalent booster effectiveness against severe COVID-19 outcomes in Finland, September 2022 – March 2023

Eero Poukka, Hanna Nohynek, Sirkka Goebeler, Tuija Leino, Ulrike Baum

Table S1:	Highly predisposing comorbidities or medical therapies	2
Table S2:	Moderately predisposing comorbidities or medical therapies	3
Table S3:	Enrollment of the study cohorts	4
Table S4:	Distribution of baseline characteristics	5
Table S5:	Hazard ratios, 65-to-110-year-olds	6
Table S6:	Hazard ratios, 65-to-79-year-olds	8
Table S7:	Hazard ratios, 80-to-110-year-olds	9
Table S8:	Hazard ratios, 65-to-110-year-olds, stratified by vaccine composition	10
Table S9:	Hazard ratios, 18-to-64-year-olds with underlying medical conditions	12
Figure S1	: Distribution of sequenced Omicron lineages in Finland	14

Classification system	Codes
Actively treated cancer	
ICD10	C00, C01, C02, C03, C04, C05, C06, C07, C08,
	C09, C10, C11, C12, C13, C14, C15, C16, C17,
	C18, C19, C20, C21, C22, C23, C24, C25, C26,
	C27, C28, C29, C30, C31, C32, C33, C34, C35,
	C36, C37, C38, C39, C40, C41, C42, C43, C45,
	C46, C47, C48, C49, C50, C51, C52, C53, C54,
	C55, C56, C57, C58, C59, C60, C61, C62, C63,
	C64, C65, C66, C67, C68, C69, C70, C71, C72,
	C73, C74, C75, C76, C77, C78, C79, C80, C81,
	C82, C83, C84, C85, C86, C87, C88, C89, C90,
	C91, C92, C93, C94, C95, C96, C97, D051, D39
Down syndrome	0.00
ICD10	$\mathbf{Q90}$
Organ or stem cell transplantation	
ICD10	T86, Z94
Severe chronic respiratory disease	
ICD10	E84, J41, J42, J43, J44, J45, J46, J47, Z902
ICPC2	R96
Severe disorder of the immune system	
ICD10	D7081, D7089, D80, D81, D82, D83, D84, E3100,
	E723, E76, E791, E792, E798, E799, Q7782, Q7800,
	Q7808, Q809, Q8900, Q8933, Q8934, Q938, Z908
NCSP	JMA
Severe kidney disease	
ICD10	E102, E112, E142, I12, I13, N00, N01, N02, N03,
	N04, N05, N07, N08, N11, N14, N18, N19
Type 2 diabetes mellitus	
ATC	A10B
ICD10	E11, E13, E14
ICPC2	T90

**Table S1: Highly predisposing comorbidities or medical therapies** Definition of comorbidities and medical therapies that were considered highly predisposing to severe COVID-19.

ATC, Anatomical Therapeutic Chemical Classification System;

ICD10, International Statistical Classification of Diseases, tenth revision;

ICPC2, International Classification of Primary Care, second edition;

NCSP, Nordic Classification of Surgical Procedures

Classification system	Codes
Autoimmune disease	
ICD10	D86, K50, K51, L40, M02, M05, M06, M07, M139,
	M45, M460, M461, M469, M941
Immunosuppressive medication	
ATC	H02AB02, H02AB04, H02AB06, H02AB07,
	L01BA01, L01XC02, L04AA06, L04AA10,
	L04AA13, L04AA18, L04AA24, L04AA26,
	L04AA29, L04AA33, L04AA37, L04AB, L04AC,
	L04AD01, L04AD02, L04AX01, L04AX03
Neurological condition affecting breathing	
ICD10	G20, G21, G22, G23, G24, G25, G26, G70, G71,
	G72, G73, G80, G81, G82, G83, I60, I61, I62, I63,
	164, 165, 166, 167, 168, 169
Psychotic disease	
ATC	N05AH02
ICD10	F20, F21, F22, F23, F24, F25, F26, F27, F28, F29
ICPC2	P72
Severe chronic liver disease	
ICD10	K702, K703, K704, K71, K72, K73, K74
Severe heart disease	
ICD10	I110, I119, I12, I130, I131, I132, I139, I15, I20, I21,
	I22, I23, I24, I25, I26, I27, I28, I418, I42, I43, I50
Sleep apnea	
ICD10	G473
NCSP	WX723, WX780
Type 1 diabetes mellitus or adrenal insufficie	ncy
ATC	A10A
ICD10	E10, E250, E271, E272, E274, E3100, E3101,
	E3108, E896
ICPC2	T89

**Table S2: Moderately predisposing comorbidities or medical therapies** Definition of comorbidities and medical therapies that were considered moderately predisposing to severe COVID-19.

ATC, Anatomical Therapeutic Chemical Classification System;

ICD10, International Statistical Classification of Diseases, tenth revision;

ICPC2, International Classification of Primary Care, second edition;

NCSP, Nordic Classification of Surgical Procedures

**Table S3: Enrollment of the study cohorts** Each target population included all individuals who were living in Finland during the study, met the age criterion at the beginning of the study, and had received at least two monovalent COVID-19 vaccine doses prior to the study.

	No. of individuals
65-to-110-year-olds	
Target population	1222237
Excluded due to hospitalisation due to COVID-19 at the beginning of the study	455
Excluded due to too short dosing interval <sup>*</sup> prior to the study	8656
Excluded due to bivalent vaccination prior to the study	27
Excluded due to right-censoring prior to the start of individual follow-up	15598
Study cohort	1197501
18-to-64-year-olds with underlying medical conditions	
Target population	450578
Excluded due to hospitalisation due to COVID-19 at the beginning of the study	163 - 166
Excluded due to too short dosing interval <sup>*</sup> prior to the study	4075
Excluded due to bivalent vaccination prior to the study	1-4
Excluded due to right-censoring prior to the start of individual follow-up	2009
Study cohort	444327

 $\ast$  less than 91 days between two doses or

less than 14 days between the first two doses (42 days if the first vaccination was with Vaxzevria)

	65-to- $110-$ year-olds	18-to-64-year-olds $*$
Age in years		
18 - 34	0  (0%)	65006~(15%)
35 - 49	0  (0%)	121544~(27%)
50-64	0 (0%)	257777~(58%)
65 - 79	890791 (74%)	0 (0%)
80 - 110	306710~(26%)	0 (0%)
Region of residence		
Helsinki-Uusimaa	287190 (24%)	130878 (29%)
Åland	6691(1%)	1851 (0%)
Northern and Eastern Finland	305550 ( $26%$ )	108736 (24%)
Southern Finland	282601 (24%)	94503 (21%)
Western Finland	315469(26%)	108359 (24%)
Sex		
Female	666298~(56%)	232350~(52%)
Male	531203~(44%)	211977~(48%)
Hospitalized in the year before the study		
No	$1042811 \ (87\%)$	402995~(91%)
Yes	154690~(13%)	41332~(9%)
Presence of comorbidities or medical therapies		
No predisposing medical conditions	614246~(51%)	0 (0%)
Only moderately predisposing medical conditions	329422(28%)	316552 (71%)
At least one highly predisposing medical condition	253833 (21%)	127775 (29%)
Long-term care		
No	$1161912 \ (97\%)$	443910 (100%)
Yes	35589~(3%)	417 (0%)
Number of vaccinations prior to the study		
2	65707~(5%)	88874 (20%)
3	478171 (40%)	296963 (67%)
4-5	653623 ( $55%$ )	58490 (13%)
Last infection prior to the study		
No prior infection	1115459~(93%)	325893~(73%)
Pre-Omicron infection	13314(1%)	14363 (3%)
Omicron infection	68728(6%)	104071 (23%)

 Table S4: Distribution of baseline characteristics
 Absolute and relative frequencies.

 $\ast$  with underlying medical conditions

**Table S5: Hazard ratios, 65-to-110-year-olds** Covariate-adjusted hazard ratios comparing the hazards of severe COVID-19 outcomes and a negative control outcome in 65-to-110-year-olds who received a bivalent COVID-19 vaccine with the corresponding hazards in those who did not receive a bivalent COVID-19 vaccine.

		Cases Person-years	Ha	Hazard ratio		
Days since bivalent vaccination	Cases		MLE	LCI	UCI	
September – December 2022						
Hospitalisation due to COV	ID-19					
No bivalent vaccination	1471	227920				
0 - 13	71	22198	0.46	0.35	0.61	
14-30	69	24199	0.41	0.31	0.55	
31 - 60	59	23754	0.37	0.27	0.50	
61 - 90	13	3159	0.66	0.38	1.17	
91-120	0	94	NE	NE	NE	
Death due to COVID-19						
No bivalent vaccination	870	228100				
0 - 13	15	22200	0.19	0.11	0.33	
14 - 30	29	24204	0.34	0.23	0.51	
31 - 60	44	23761	0.47	0.33	0.66	
61-90	7 - 10	3160	0.50	0.25	0.99	
91–120	1-4	95	3.34	0.82	13.62	
Death in which COVID-19	was a co	ntributing fa	rtor			
No bivalent vaccination	705	228100				
0-13	4-7	22200	0.11	0.05	0.23	
14-30	31	24204	0.40	0.27	0.60	
31-60	40	23761	$0.10 \\ 0.45$	0.21	0.64	
61-90	10	3160	$0.10 \\ 0.42$	0.01	0.0	
91-120	1-4	95	2.09	0.29	15.09	
Emergency room visit due t		7		0.20		
No bivalent vaccination	7702 7702	226800				
$0_{-13}$	622	220033 22077	0.86	0.78	0.05	
14_30	680	24052	0.80	0.78	0.90	
31_60	710	24052 23507	0.00	0.10	1.0	
61 00	110	20091	0.92	0.84 0.74	1.02	
01-90 01 120	00	04	0.92 NF	0.74 NF	1.10 NE	
91–120 March 2000	0	94	INE	INE:	INE	
January – March 2023						
Hospitalisation due to COV	ID-19					
No bivalent vaccination	147	108817				
0 - 13	1-4	2506	1.23	0.45	3.38	
14 - 30	11	5663	1.24	0.65	2.38	
31 - 60	32	28213	0.71	0.46	1.12	
61-90	51	46267	0.95	0.65	1.4(	
91–120	38	43788	0.78	0.51	1.19	
121 - 150	41	23061	1.23	0.79	1.91	
151 - 180	6 - 9	2976	1.21	0.51	2.86	
181 - 211	0	86	NE	NE	NE	
Death due to COVID-19						
No bivalent vaccination	99	108872				
0 - 13	0	2506	NE	NE	NE	
14–30	2 - 5	5664	0.81	0.32	2.05	
31 - 60	29	28222	0.86	0.52	1.41	

(Table 55 continued)					
Days since bivalent vaccination	Cases	Person-years	MLE	LCI	UCI
61–90	35	46280	0.85	0.54	1.35
91 - 120	18	43796	0.75	0.42	1.33
121 - 150	11	23065	0.90	0.44	1.87
151 - 180	1 - 4	2977	0.50	0.07	3.80
181 - 211	0	86	NE	NE	NE
Death in which COVID-19	was a co	ontributing fa	$\operatorname{ctor}$		
No bivalent vaccination	100	108872			
0 - 13	1 - 4	2506	0.30	0.04	2.19
14 - 30	1 - 4	5664	0.41	0.15	1.14
31 - 60	22	28222	0.40	0.24	0.67
61 - 90	28	46280	0.41	0.25	0.65
91 - 120	25	43796	0.82	0.49	1.37
121 - 150	13	23065	1.30	0.63	2.66
151 - 180	0	2977	NE	NE	NE
181 - 211	0	86	NE	NE	NE
Emergency room visit due	to injury	7			
No bivalent vaccination	2746	107540			
0 - 13	68 - 71	2478	1.12	0.88	1.42
14 - 30	153	5599	1.07	0.90	1.26
31 - 60	724	27926	0.97	0.88	1.07
61 - 90	1194	45779	0.97	0.89	1.05
91 - 120	1103	43272	0.95	0.88	1.04
121 - 150	605	22775	0.93	0.83	1.03
151 - 180	79	2938	0.88	0.70	1.11
181-211	1 - 4	85	1.12	0.36	3.50

(Table S5 continued)

MLE, maximum likelihood estimate;

LCI/UCI, lower/upper limit of the 95% Wald confidence interval;

Table S6: Hazard ratios, 65-to-79-year-olds Covariate-adjusted hazard ratios comparing the hazards of severe COVID-19 outcomes in 65-to-79-year-olds who received a bivalent COVID-19 vaccine with the corresponding hazards in those who did not receive a bivalent COVID-19 vaccine.

			Haz	zard ra	tio
Days since bivalent vaccination	Cases	Person-years	MLE	LCI	UCI
September – December 2022					
Hospitalisation due to COV	ID-19				
No bivalent vaccination	626	156640			
0 - 13	25	15707	0.41	0.26	0.63
14-60	72	33421	0.55	0.40	0.75
61 - 120	7	2283	0.83	0.38	1.79
Death due to COVID-19					
No bivalent vaccination	190	156721			
0 - 13	7	15707	0.43	0.19	0.97
14-60	15	33426	0.44	0.24	0.81
61 - 120	ND	2284	0.60	0.14	2.56
Death in which COVID-19	was a co	ontributing fa	$\operatorname{ctor}$		
No bivalent vaccination	172	156721			
0 - 13	ND	15707	0.07	0.01	0.54
14 - 60	14	33426	0.44	0.23	0.86
61 - 120	ND	2284	0.65	0.15	2.74
January – March 2023					
Hospitalisation due to COV	ID-19				
No bivalent vaccination	82	85025			
0 - 13	ND	1989	0.54	0.07	3.93
14-60	24	25251	0.90	0.52	1.55
61 - 120	49	64282	0.95	0.60	1.49
121 - 180	ND	18181	1.80	1.03	3.14
181 - 211	0	67	NE	NE	NE
Death due to COVID-19					
No bivalent vaccination	33	85053			
0 - 13	0	1989	NE	NE	NE
14-60	ND	25256	0.42	0.17	1.04
61 - 120	9	64295	0.33	0.14	0.78
121-180	ND	18184	0.45	0.11	1.77
181 - 211	0	67	NE	NE	NE
Death in which COVID-19	was a co	ontributing fa	ctor		
No bivalent vaccination	30	85053			
0 - 13	ND	1989	0.93	0.12	7.06
14-60	ND	25256	0.63	0.27	1.46
61–120	10	64295	0.37	0.16	0.86
121 - 180	7	18184	2.08	0.71	6.08
181 - 211	0	67	NE	NE	NE

MLE, maximum likelihood estimate;

 $\rm LCI/UCI,$  lower/upper limit of the 95% Wald confidence interval;

ND, not disclosed;

Table S7: Hazard ratios, 80-to-110-year-olds Covariate-adjusted hazard ratios comparing the hazards of severe COVID-19 outcomes in 80-to-110-year-olds who received a bivalent COVID-19 vaccine with the corresponding hazards in those who did not receive a bivalent COVID-19 vaccine.

			Haz	zard ra	tio
Days since bivalent vaccination	Cases	Person-years	MLE	LCI	UCI
September – December 2022					
Hospitalisation due to COV	ID-19				
No bivalent vaccination	845	71280			
0 - 13	46	6491	0.48	0.34	0.69
14-60	56	14533	0.28	0.20	0.39
61 - 120	6	970	0.53	0.23	1.21
Death due to COVID-19					
No bivalent vaccination	680	71380			
0 - 13	8	6493	0.13	0.06	0.27
14-60	58	14539	0.39	0.28	0.55
61 - 120	ND	971	0.58	0.29	1.16
Death in which COVID-19	was a co	ontributing fa	$\operatorname{ctor}$		
No bivalent vaccination	533	71380			
0 - 13	ND	6493	0.12	0.05	0.27
14-60	57	14539	0.41	0.30	0.58
61 - 120	ND	971	0.42	0.18	0.97
January – March 2023					
Hospitalisation due to COV	ID-19				
No bivalent vaccination	65	23792			
$0\!-\!13$	ND	518	2.09	0.63	6.90
14-60	19	8625	0.67	0.36	1.25
61 - 120	40	25773	0.80	0.48	1.33
121 - 180	ND	7856	0.81	0.42	1.55
181 - 211	0	20	NE	NE	NE
Death due to COVID-19					
No bivalent vaccination	66	23819			
0 - 13	0	518	NE	NE	NE
14-60	ND	8630	1.10	0.63	1.91
61 - 120	44	25782	1.10	0.69	1.78
121 - 180	ND	7858	1.12	0.49	2.56
181 - 211	0	20	NE	NE	NE
Death in which COVID-19	was a co	ontributing fa	$\operatorname{ctor}$		
No bivalent vaccination	70	23819			
0 - 13	0	518	NE	NE	NE
14-60	ND	8630	0.34	0.18	0.62
61 - 120	43	25782	0.57	0.36	0.91
121 - 180	6	7858	0.65	0.24	1.74
181 - 211	0	20	NE	NE	NE

MLE, maximum likelihood estimate;

 $\rm LCI/UCI,$  lower/upper limit of the 95% Wald confidence interval;

ND, not disclosed;

Table S8: Hazard ratios, 65-to-110-year-olds, stratified by vaccine composition Covariate-adjusted hazard ratios comparing the hazards of severe COVID-19 outcomes in 65-to-110-year-olds who received a bivalent COVID-19 vaccine with the corresponding hazards in those who did not receive a bivalent COVID-19 vaccine distinguishing between BA.1 and BA.4-5 bivalent vaccines.

			Ha	zard ra	atio
Days since bivalent vaccination	Cases	Person-years	MLE	LCI	UCI
September – December 2022					
Hospitalisation due to COV	ID-19				
No bivalent vaccination	1471	227920			
BA.1 bivalent vaccine					
0–13	20	6970	0.38	0.24	0.61
14-60	39	15422	0.34	0.24	0.48
61-120	9-12	1746	0.88	0.46	1.66
BA.4-5 bivalent vaccine					
0-13	51	15228	0.50	0.37	0.68
14-60	89	32531	0.42	0.33	0.55
61-120	1-4	1507	0.35	0.11	1.10
Death due to COVID-19					
No bivalent vaccination	870	228100			
BA.1 bivalent vaccine					
0-13	1-4	6971	0.17	0.06	0.46
14-60	16	15426	0.29	0.17	0.48
61-120	ND	1747	0.80	0.35	1.82
BA.4-5 bivalent vaccine					
0-13	11-14	15229	0.21	0.11	0.38
14-60	57 ND	32540	0.46	0.34	0.63
61–120 D	ND	1508	0.44	0.18	1.09
Death in which COVID-19	was a co	ontributing fa	$\operatorname{ctor}$		
No bivalent vaccination	705	228100			
BA.1 bivalent vaccine					
0-13	ND	6971	0.21	0.08	0.57
14-60	18	15426	0.36	0.22	0.60
61-120	ND	1747	0.58	0.21	1.58
BA.4-5 bivalent vaccine					
0-13	ND	15229	0.07	0.02	0.21
14-60	53 ND	32540	0.45	0.33	0.63
61-120	ND	1508	0.38	0.14	1.04
January – March 2023					
Hospitalisation due to COV	ID-19				
No bivalent vaccination	147	108817			
BA.1 bivalent vaccine					
0 - 13	ND	479	1.62	0.22	11.70
14-60	5	9410	0.34	0.13	0.85
61-120	16	27420	0.55	0.31	0.96
121–180	ND	9039	0.95	0.49	1.85
BA.4-5 bivalent vaccine					
0–13	ND	2027	1.13	0.35	3.59
14-60	$\frac{38}{-2}$	24466	0.96	0.63	1.47
61 - 120	73	62635	1.02	0.71	1.45

Days since bivalent vaccination	Cases	Person-years	MLE	LCI	UCI
191 190	ND	16000	1 45	0.02	2.20
121-180	ND.	10998	1.40	0.92	2.30
BA.1 and BA.4-5 bivalent vacca	ines	00	NE	NE	NE
181–211	0	86	NE	NE	NE
Death due to COVID-19					
No bivalent vaccination	99	108872			
BA.1 bivalent vaccine					
0 - 13	0	479	NE	NE	NE
14-60	ND	9412	0.84	0.41	1.70
61 - 120	20	27425	1.07	0.62	1.85
121 - 180	ND	9041	0.94	0.32	2.71
BA.4-5 bivalent vaccine					
$0\!-\!13$	0	2027	NE	NE	NE
14-60	ND	24473	0.85	0.51	1.43
61 - 120	33	62651	0.70	0.44	1.12
121 - 180	ND	17001	0.82	0.36	1.87
BA.1 and BA.4-5 bivalent vacca	ines				
181 - 211	0	86	NE	NE	NE
Death in which COVID-19 v	vas a co	ontributing fac	$\operatorname{ctor}$		
No bivalent vaccination	100	108872			
BA.1 bivalent vaccine					
0 - 13	ND	479	1.55	0.21	11.24
14-60	ND	9412	0.70	0.36	1.34
61 - 120	18	27425	0.71	0.41	1.23
121 - 180	1 - 4	9041	1.09	0.37	3.17
BA.4-5 bivalent vaccine					
0-13	0	2027	NE	NE	NE
14-60	ND	24473	0.31	0.17	0.57
61 - 120	35	62651	0.46	0.29	0.72
121 - 180	9 - 12	17001	0.98	0.43	2.21
BA.1 and BA.4-5 bivalent vacca	ines				
181–211	0	86	NE	NE	NE

(Table S8 continued)

MLE, maximum likelihood estimate;

LCI/UCI, lower/upper limit of the 95% Wald confidence interval;

ND, not disclosed;

Table S9: Hazard ratios, 18-to-64-year-olds with underlying medical conditions Covariateadjusted hazard ratios comparing the hazards of severe COVID-19 outcomes and a negative control outcome in 18-to-64-year-olds with underlying medical conditions who received a bivalent COVID-19 vaccine with the corresponding hazards in those who did not receive a bivalent COVID-19 vaccine.

			Ha	zard ra	atio
Days since bivalent vaccination	Cases	Person-years	MLE	LCI	UCI
September – December 2022					
Hospitalisation due to COV	ID-19				
No bivalent vaccination	204	119381			
0 - 13	1 - 4	2231	0.16	0.02	1.16
14 - 30	6	2367	1.01	0.43	2.40
31 - 60	9	2408	1.81	0.87	3.76
61 - 90	1 - 4	517	3.82	1.17	12.43
91 - 120	0	21	NE	NE	NE
Death due to COVID-19					
No bivalent vaccination	14	119406			
0 - 13	0	2231	NE	NE	NE
14 - 30	0	2367	NE	NE	NE
31 - 60	0	2408	NE	NE	NE
61 - 90	0	517	NE	NE	NE
91 - 120	0	21	NE	NE	NE
Death in which COVID-19	was a co	ontributing fa	$\operatorname{ctor}$		
No bivalent vaccination	14	119406			
0 - 13	0	2231	NE	NE	NE
14 - 30	1 - 4	2367	2.23	0.24	20.88
31 - 60	1 - 4	2408	2.31	0.24	22.22
61 - 90	0	517	NE	NE	NE
91 - 120	0	21	NE	NE	NE
Emergency room visit due t	o injury	y			
No bivalent vaccination	2085	119057			
0 - 13	56	2222	1.51	1.14	2.00
14 - 30	54	2356	1.40	1.05	1.87
31 - 60	37	2396	1.00	0.71	1.41
61 - 90	15	514	2.02	1.21	3.40
91 - 120	0	20	NE	NE	NE
January – March 2023					
Hospitalisation due to COV	ID-19				
No bivalent vaccination	35	81328			
0 - 13	0	499	NE	NE	NE
14 - 30	1 - 4	922	1.32	0.17	10.05
31 - 60	2	3217	0.74	0.16	3.30
61 - 90	7	4644	2.60	1.04	6.48
91 - 120	7	4319	3.40	1.34	8.66
121 - 150	2	2321	2.05	0.44	9.51
151 - 180	1 - 4	486	5.33	0.66	42.76
181 - 211	0	19	NE	NE	NE
Death due to COVID-19					
No bivalent vaccination	1 - 4	81339			
0 - 13	0	499	NE	NE	NE
14 - 30	0	922	NE	NE	NE

(Table 55 continued)					
Days since bivalent vaccination	Cases	Person-years	MLE	LCI	UCI
31-60	1-4	3218	NE	NE	NE
61–90	0	4645	NE	NE	NE
91 - 120	0	4320	NE	NE	NE
121 - 150	0	2321	NE	NE	NE
151 - 180	0	486	NE	NE	NE
181 - 211	0	19	NE	NE	NE
Death in which COVID-19 was a contributing factor					
No bivalent vaccination	1 - 4	81339			
0 - 13	0	499	NE	NE	NE
14-30	0	922	NE	NE	NE
31-60	1 - 4	3218	NE	NE	NE
61–90	0	4645	NE	NE	NE
91 - 120	0	4320	NE	NE	NE
121 - 150	0	2321	NE	NE	NE
151 - 180	0	486	NE	NE	NE
181 - 211	0	19	NE	NE	NE
Emergency room visit due to injury					
No bivalent vaccination	1244	80729			
$0\!-\!13$	6	495	0.80	0.36	1.78
14 - 30	16	915	1.14	0.69	1.88
31 - 60	61	3194	1.21	0.92	1.59
61 - 90	76	4608	1.11	0.87	1.42
91 - 120	75	4281	1.20	0.93	1.53
121 - 150	34	2299	0.96	0.67	1.37
151 - 180	6	480	0.76	0.34	1.71
181 - 211	0	19	NE	NE	NE

(Table S9 continued)

MLE, maximum likelihood estimate;

LCI/UCI, lower/upper limit of the 95% Wald confidence interval;

Figure S1: Distribution of sequenced Omicron lineages in Finland The graph shows the percentages of the most frequent SARS-CoV-2 sublineages detected by sentinel surveillance and recorded in the National Infectious Diseases Register by week of sample collection since August 2022. Green bars represent BA.2 sublineages (BA.2 lineages, BA.2.75.X and CH.1.1.X), orange bars represent BA.4 sublineages and pink bars represent BA.5 sublineages (BA.5 lineages, BF.7.X and BQ.1.X). The grey bars represent recombinant lineages (XBB, XBB.1.5, XBB.1.9.1.X, XBB.1.16.X and XBF) as well as the group 'Other variants', which comprises all sublineages not assigned to any of the previous groups. The .X extension covers the whole sublineage family, e.g. BQ.1.X covers all descendants of BQ.1, such as BQ.1.1 and BQ.1.2.



 $\label{eq:label} Adapted from https://thl.fi/en/web/infectious-diseases-and-vaccinations/what-s-new/coronavirus-covid-19-latest-updates/coronavirus-variants/genomic-surveillance-of-sars-cov-2$